| __timestamp | Agios Pharmaceuticals, Inc. | Blueprint Medicines Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 7890000 |
| Thursday, January 1, 2015 | 35992000 | 14456000 |
| Friday, January 1, 2016 | 50714000 | 19218000 |
| Sunday, January 1, 2017 | 71124000 | 27986000 |
| Monday, January 1, 2018 | 114145000 | 47928000 |
| Tuesday, January 1, 2019 | 132034000 | 96388000 |
| Wednesday, January 1, 2020 | 149070000 | 157743000 |
| Friday, January 1, 2021 | 121445000 | 195293000 |
| Saturday, January 1, 2022 | 121673000 | 237374000 |
| Sunday, January 1, 2023 | 119903000 | 295141000 |
| Monday, January 1, 2024 | 156784000 | 359272000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing operational expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Blueprint Medicines has seen a staggering increase in SG&A expenses, growing nearly 3,700% from 2014 to 2023. In contrast, Agios Pharmaceuticals experienced a more modest increase of approximately 525%.
Blueprint's expenses surged particularly from 2020 onwards, reflecting its aggressive expansion and investment in commercial operations. Meanwhile, Agios maintained a steadier growth trajectory, indicating a more conservative approach. This divergence highlights different strategic priorities: Blueprint's focus on rapid growth versus Agios's emphasis on sustainable scaling. Understanding these trends offers valuable insights into how these companies navigate the financial demands of the biotech industry.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Agios Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Xenon Pharmaceuticals Inc. and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Catalyst Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.